PDF下载 ( 1845 KB)
Pathogenesis of cholestasis-induced liver fibrosis and thoughts for blockade
-
摘要:
胆汁淤积是指胆汁流形成、分泌和排泄障碍的一种病理状态,而肝纤维化是肝损伤引起的组织修复过程。胆汁淤积性肝病是由胆汁淤积、胆管渐进性破坏和肝内炎症持续存在所导致的一种慢性肝病,引起胆管细胞和肝细胞损伤,并逐步进展为肝纤维化。结合目前的研究进展,对胆汁淤积导致肝纤维化的发生机制和阻断策略作一综述。
Abstract:Cholestasis refers to a pathological state of disorders in the formation, secretion, and excretion of bile flow, and liver fibrosis is a process of tissue repair induced by liver injury. Cholestatic liver disease is a chronic liver disease caused by cholestasis, progressive bile duct injury, and persistent intrahepatic inflammation, and it may cause cholangiocyte and hepatocyte injury, which will gradually progress to liver fibrosis. With reference to the current research advances, this article reviews the pathogenesis of cholestasis-induced liver fibrosis and the strategies for blockade.
-
Key words:
- cholestasis /
- liver cirrhosis /
- bile acids and salts
-
[1]POLLHEIMER MJ, FICKERT P, STIEGER B.Chronic cholestatic liver diseases:Clues from histopathology for pathogenesis[J].Mol Aspects Med, 2014, 37:35-56. [2]WELLS RG, SCHWABE RF.Origin and function of myofibroblasts in the liver[J].Semin Liver Dis, 2015, 35 (2) :e1. [3]TSUCHIDA T, FRIEDMAN SL.Mechanisms of hepatic stellate cell activation[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (7) :397-411. [4]FRIEDMAN SL.Hepatic stellate cells:Protean, multifunctional, and enigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172. [5]HIGASHI T, FRIEDMAN SL, HOSHIDA Y.Hepatic stellate cells as key target in liver fibrosis[J].Adv Drug Deliv Rev, 2017, 121:27-42. [6]MEDERACKE I, HSU CC, TROEGER JS, et al.Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology[J].Nat Commun, 2013, 4:2823. [7]IWAISAKO K, JIANG C, ZHANG M, et al.Origin of myofibroblasts in the fibrotic liver in mice[J].Proc Natl Acad Sci U S A, 2014, 111 (32) :e3297-e3305. [8]DRANOFF JA, WELLS RG.Portal fibroblasts:Underappreciated mediators of biliary fibrosis[J].Hepatology, 2010, 51 (4) :1438-1444. [9]KINNMAN N, HOUSSET C.Peribiliary myofibroblasts in biliary type liver fibrosis[J].Front Biosci, 2002, 7:d496-d503. [10]KISSELEVA T, UCHINAMI H, FEIRT N, et al.Bone marrowderived fibrocytes participate in pathogenesis of liver fibrosis[J].J Hepatol, 2006, 45 (3) :429-438. [11]SCHOLTEN D, OSTERREICHER CH, SCHOLTEN A, et al.Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice[J].Gastroenterology, 2010, 139 (3) :987-998. [12]CHU AS, DIAZ R, HUI JJ, et al.Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis[J].Hepatology, 2011, 53 (5) :1685-1695. [13]JANSEN PL, GHALLAB A, VARTAK N, et al.The ascending pathophysiology of cholestatic liver disease[J].Hepatology, 2017, 65 (2) :722-738. [14]YIN XM, DING WX.Death receptor activation-induced hepatocyte apoptosis and liver injury[J].Curr Mol Med, 2003, 3 (6) :491-508. [15]BORGOGNONE M, PREZ LM, BASIGLIO CL, et al.Signaling modulation of bile salt-induced necrosis in isolated rat hepatocytes[J].Toxicol Sci, 2005, 83 (1) :114-125. [16]SAKISAKA S, KAWAGUCHI T, TANIGUCHI E, et al.Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis[J].Hepatology, 2001, 33 (6) :1460-1468. [17]HOHENESTER S, WENNIGER LM, PAULUSMA CC, et al.Abiliary HCO-3umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes[J].Hepatology, 2012, 55 (1) :173-183. [18]MEDINA JF, MARTNEZ-ANS, VAZQUEZ JJ, et al.Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis[J].Hepatology, 1997, 25 (1) :12-17. [19]WILLIAMS MJ, CLOUSTON AD, FORBES SJ.Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion[J].Gastroenterology, 2014, 146 (2) :349-356. [20]ROSKAMS TA, THEISE ND, BALABAUD C, et al.Nomenclature of the finer branches of the biliary tree:Canals, ductules, and ductular reactions in human livers[J].Hepatology, 2004, 39 (6) :1739-1745. [21]ROSKAMS T, DESMET V.Ductular reaction and its diagnostic significance[J].Semin Diagn Pathol, 1998, 15 (4) :259-269. [22]STRAZZABOSCO M, FABRIS L.Development of the bile ducts:Essentials for the clinical hepatologist[J].J Hepatol, 2012, 56 (5) :1159-1170. [23]KINNMAN N, FRANCOZ C, BARBU V, et al.The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis[J].Lab Invest, 2003, 83 (2) :163-173. [24]PRIESTER S, WISE C, GLASER SS.Involvement of cholangiocyte proliferation in biliary fibrosis[J].World J Gastrointest Pathophysiol, 2010, 1 (2) :30-37. [25]VARTAK N, DAMLE-VARTAK A, RICHTER B, et al.Cholestasis-induced adaptive remodeling of interlobular bile ducts[J].Hepatology, 2016, 63 (3) :951-964. [26]POUPON RE, BONNAND AM, CHRTIEN Y, et al.Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.The UDCA-PBC Study Group[J].Hepatology, 1999, 29 (6) :1668-1671. [27] TRAUNER M, FUCHS CD, HALILBASIC E, et al.New therapeutic concepts in bile acid transport and signaling for management of cholestasis[J].Hepatology, 2017, 65 (4) :1393-1404. [28]GERKEN G, NITSCHMANN S.Obeticholic acid in primary biliary cholangitis:PBC OCA international study of efficacy (POISE) [J].Internist (Berl) , 2017, 58 (2) :202-204. [29]LEUSCHNER M, MAIER KP, SCHLICHTING J, et al.Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis:Results of a prospective double-blind trial[J].Gastroenterology, 1999, 117 (4) :918-925. [30]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323. [31]RAUTIAINEN H, KRKKINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:A three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752. [32]PATSENKER E, POPOV Y, STICKEL F, et al.Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression[J].Gastroenterology, 2008, 135 (2) :660-670. [33]PENG ZW, IKENAGA N, LIU SB, et al.Integrinανβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis[J].Hepatology, 2016, 63 (1) :217-232. [34]HAZRA S, XIONG S, WANG J, et al.Peroxisome proliferatoractivated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells[J].J Biol Chem, 2004, 279 (12) :11392-11401. [35]STAELS B, RUBENSTRUNK A, NOEL B, et al.Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].Hepatology, 2013, 58 (6) :1941-1952. [36]RATZIU V, HARRISON SA, FRANCQUE S, et al.Elafibranor, an agonist of the peroxisome proliferator-activated receptor-αand-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J].Gastroenterology, 2016, 150 (5) :1147-1159. [37]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :Amulticentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965. [38]MEISSNER EG, McLAUGHLIN M, MATTHEWS L, et al.Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults:Results of a 6-month open-label safety trial[J].Liver Int, 2016, 36 (12) :1783-1792. -
本文二维码
计量
- 文章访问数: 2169
- HTML全文浏览量: 31
- PDF下载量: 550
- 被引次数: 0
下载:
